Growth of a transplanted Walker 256 carcinosarcoma in rats was accompanied by: 1) An increase in plasma fibrinogen and urinary trypsin inhibitors; 2) A significant decrease in plasma plasminogen and hematocrit; 3) A decrease in urokinase activity in urine; 4) A decrease in fibrinolytic activity of the euglobulin fraction of plasma and serum. There was no significant change in the plasma inhibitors for trypsin or bovine fibrinolysin.
Get full access to this article
View all access options for this article.
References
1.
BaleW. F., SparI. L., and GoodlandR. L.: Experimental radiation therapy of tumors with I131 carrying antibodies to fibrin. Cancer Res., 20: 1488–1494, 1960.
2.
BangN. U., FreimanA. H., and ClifftonE. E.: Effect of increased fibrinogen concentration on the lysis of in vivo thrombi. Circulat. Res., 8: 419–422, 1960.
3.
BaumgartenW., PriesterL. I., HerczegS. A., and WatsonL. S.: Evaluation of the fibrinolytic state after administration of Urokinases. Proc. Soc. exp. Biol. Med., 115: 1120–1124, 1964.
4.
ClifftonE. E.: An evaluation of antiproteolytic reaction of serum as a test for malignant neoplasia. J. nat. Cancer Inst., 11: 35–50, 1950.
5.
ClifftonE. E., and AgostinoD.: The effect of fibrin formation and alterations of the clotting mechanism on the development of metastases. J. Vasc. Dis., 2: 43–52, 1965.
6.
DayE. D., PlaninsekJ. A., and PressmanD.: Localization of radio-iodinated rat fibrinogen in transplanted rat tumors. J. nat. Cancer Inst., 23: 799–812, 1959.
7.
GirolamiA., and ClifftonE. E.: Fibrinolytic and proteolytic activity in acute and chronic leukemia. Amer. med. Sci., 251: 638–644, 1966.
8.
GirolamiA., MootseG., and ClifftonE. E.: Blood plasminogen (Profibrinolysin) levels in patients with leukemia and lymphoma. Amer. I. med. Sci., 254: 334–340, 1967.
9.
HoerS. O., and HarperJ. R.: On peripheral thrombophlebitis; its occurrence as a presenting symptom in malignant disease of pancreas, biliary tract or duodenum. J.A.M.A., 164: 2033–2034, 1957.
10.
IwasakiT.: Histological and experimental observations on the destruction of tumor cells in the blood. J. Path. Bact., 20: 85–105, 1915.
11.
LawrenceE. A., BrownD. E., MooreD. B., and BernsteinG. I.: A thromboplastic property of neoplasma. Surg. Forum, 3: 694–698, 1952.
12.
KeilE.: Gerinnungsfaktoren und Krebs. Strahlen-therapie, 93: 223–235, 1954.
13.
MootseG., AgostinoD., and ClifftonE. E.: Alterations in fibrinogen, plasminogen and inhibitors of plasmin with the growth of V2 carcinoma in rabbits. J. nat. Cancer Inst., 35: 567–572, 1965.
14.
NusbacherJ.: Migratory venous thrombosis and cancer. N. Y. J. Med., 64: 2166–2173, 1964.
15.
O'MearaR. A. Q.: Coagulative properties of cancer. Irish J. med. Sci., 6: 474–479, 1958.
16.
ProkopowiczJ.: Purification of plasminogen from human granulocytes, using DEAE-Sephadex column chromatography. Biochem. Biophys. Acta, 154: 91–95, 1968.
17.
RudenstamC. M.: Experimental studies on trauma and metastasis.Goteborg Elanders Boktrykeri, Aktiebulag, 1968.
18.
SaphirG.: Fate of carcinoma emboli in the lung. Amer. J. Path., 23: 245–254, 1947.
19.
WatanabeS.: Metastasizability of tumor cells. Cancer, 7: 215–223, 1954.
20.
WoodS.Jr.: Experimental studies of the intravascular dissemination of ascites V2 carcinoma cells in the rabbit, with special reference to fibrinogen and fibrinolytic agents. Bull. Swiss Acad. Med. Sci., 20: 92–121, 1964.
